PharmaEssentia Expands North American Commercial Footprint with Acquisition of Canadian Partner FORUS Therapeutics
Acquisition deepens PharmaEssentia’s presence in the Canadian hematology-oncology MPN market to accelerate BESREMi® (ropeginterferon alfa-2b) commercialization BURLINGTON, Mass. — PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan, today announced the acquisition of FORUS Therapeutics Inc. (“FORUS”), a Canadian specialty pharmaceutical company, in a transaction valued at US$36.5 million. The acquisition represents an [̷...
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.